Literature DB >> 2182155

Lipid lowering drugs.

P O'Connor1, J Feely, J Shepherd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2182155      PMCID： PMC1662400          DOI： 10.1136/bmj.300.6725.667

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  30 in total

1.  High density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men.

Authors:  S J Pocock; A G Shaper; A N Phillips; M Walker; T P Whitehead
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-22

2.  Drug treatment for hypercholesterolaemia.

Authors:  M J Ball; J I Mann
Journal:  Q J Med       Date:  1986-08

Review 3.  HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.

Authors:  S M Grundy
Journal:  N Engl J Med       Date:  1988-07-07       Impact factor: 91.245

Review 4.  Pathogenesis and management of lipoprotein disorders.

Authors:  E J Schaefer; R I Levy
Journal:  N Engl J Med       Date:  1985-05-16       Impact factor: 91.245

Review 5.  How LDL receptors influence cholesterol and atherosclerosis.

Authors:  M S Brown; J L Goldstein
Journal:  Sci Am       Date:  1984-11       Impact factor: 2.142

6.  Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism.

Authors:  J Shepherd; C J Packard; S Bicker; T D Lawrie; H G Morgan
Journal:  N Engl J Med       Date:  1980-05-29       Impact factor: 91.245

7.  Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect.

Authors:  U Goldbourt; E Holtzman; H N Neufeld
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-27

8.  Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.

Authors:  J Rouffy; B Chanu; R Bakir; F Djian; J Goy-Loeper
Journal:  Atherosclerosis       Date:  1985-03       Impact factor: 5.162

9.  Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients.

Authors:  G Niort; A Bulgarelli; M Cassader; G Pagano
Journal:  Atherosclerosis       Date:  1988-06       Impact factor: 5.162

10.  Effects of probucol on xanthomata regression in familial hypercholesterolemia.

Authors:  A Yamamoto; Y Matsuzawa; S Yokoyama; T Funahashi; T Yamamura; B Kishino
Journal:  Am J Cardiol       Date:  1986-06-27       Impact factor: 2.778
View more
  14 in total

1.  Drug utilization in general practice: prescribing habits of National Formulary drugs by GPs of Emilia Romagna (Italy) in 1988 and 1989.

Authors:  N Montanaro; N Magrini; A Vaccheri; M Battilana
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Lipid lowering drugs.

Authors:  T S Bocanegra; J A Tobert
Journal:  BMJ       Date:  1990-05-05

3.  Fibrate monotherapy and profound hypoalphalipoproteinaemia.

Authors:  A O Olukoga; V E Crowley; M F Stewart; O Weinkove
Journal:  Postgrad Med J       Date:  1996-03       Impact factor: 2.401

4.  Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.

Authors:  D J Betteridge; P M Dodson; P N Durrington; E A Hughes; M F Laker; D P Nicholls; J A Rees; C A Seymour; G R Thompson; A F Winder
Journal:  Postgrad Med J       Date:  1993-05       Impact factor: 2.401

Review 5.  Statins for children with familial hypercholesterolemia.

Authors:  Alpo Vuorio; Jaana Kuoppala; Petri T Kovanen; Steve E Humphries; Serena Tonstad; Albert Wiegman; Euridiki Drogari; Uma Ramaswami
Journal:  Cochrane Database Syst Rev       Date:  2017-07-07

Review 6.  Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.

Authors:  M Haria; D McTavish
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 7.  Pravastatin: a review of its use in elderly patients.

Authors:  Lynne M Bang; Karen L Goa
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 9.  Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia.

Authors:  Anita Malhotra; Nusrat Shafiq; Anjuman Arora; Meenu Singh; Rajendra Kumar; Samir Malhotra
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10

10.  Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia.

Authors:  D Crook; R Bruce; M Worthington; D Mulcahy; D Patterson; V Wynn
Journal:  Cardiovasc Drugs Ther       Date:  1992-12       Impact factor: 3.727
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.